58 Cases of Malignant Pheochromocytoma Treated by 131 I MIBG——therapeutic Results and Adverse Events

Jun Zhu

1999-01-01

Abstract:Objective Clinical experience in treatment of 58 cases of malignant pheochromocytoma with metastasis is hereby reported Methods Monthly intravenous injection of 131 I MIBG 2590～3700 MBq was instituted for 6 months, afterwards, treatment of the same dose was resumed at 2～3 month interval for another 1～3 doses MIRD was applied to estimate the tumor absorption dose Results Patients were classified into 3 groups according to their tumor size In the first group, the tumor was 8 cm 3 (11 cases), in the second group, 8～20 cm 3 (21 cases), and in the third group, the tumor size was 20 cm 3 (26 cases) In the first group, the mean absorption dose was 12924 4 cGy and the absorption dose per gram of tumor was above 1000 cGy After treatment, tumors disappeared in all patients, attaining treatment goal In the second group, the absorption dose was similar to that of the first group, but the mean absorption dose per gram was 717 6 cGy, and tumor mass regression was only 36% (8 cases) 76% (16 cases) showed reduced urinary catecholamine; however, 64% showed no regression of tumor size In the third group, the absorption dose per gram tumor tissue was 277 cGy, and 30% demonstrated tumor enlargement, 20% of the patients died; the remaining 50% showed symptomatic improvement without any change in tumor size In 58 cases, 3, 5, 10 year follow up was carried out The results showed that 131 I MIBG treatment did not demonstrate significant bone marrow suppression; only 5 1% had severe bone marrow suppression, and for most of them, bone marrow suppression was only temporary Furthermore, bone marrow suppression was not related to the 131 I MIBG dosage been used in the treatment Conclusions 131 I MIBG is of certain therapeutic effectiveness of symptomatic improvement, such as blood pressure and urinary catecholamine decreasing However, complete tumor mass disappearance has only been found in small tumors Thus, treatment with 131 I MIBG should be instituted immediately after surgical resection to eradicate the residual tumor cells and to prevent recurrences Bone marrow suppression is temporary and not dosage related Treatment can be reinstituted after several weeks